Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects

被引：0
|
作者：
Song Mu
Zhiyu Tang
William Novotny
Manal Tawashi
Ta-Kai Li
Ying Ou
Srikumar Sahasranaman
机构：
[1] BeiGene USA,Clinical Pharmacology
[2] BeiGene USA,Clinical Development
[3] BeiGene USA,Clinical Operations
[4] BeiGene USA,Drug Safety and Pharmacovigilance
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 85卷
关键词：
Clinical pharmacology; Clinical trials; Drug–drug interactions; Oncology; Pharmacokinetics and drug metabolism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：391 / 399
页数：8
相关论文
共 50 条
  • [1] Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects
    Mu, Song
    Tang, Zhiyu
    Novotny, William
    Tawashi, Manal
    Li, Ta-Kai
    Ou, Ying
    Sahasranaman, Srikumar
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (02) : 391 - 399
  • [2] EFFECT OF A PROTON PUMP INHIBITOR ON THE PHARMACOKINETICS OF THE BRUTON'S TYROSINE KINASE INHIBITOR, EVOBRUTINIB, IN HEALTHY SUBJECTS.
    Mitchell, D.
    Port, A.
    Schmidt, R.
    Scheible, H.
    Bachmann, A.
    Mammasse, N.
    Dyroff, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S66 - S66
  • [3] Pharmacokinetics and Target Attainment of Ceftobiprole in Asian and Non-Asian Subjects
    Muller, A. E.
    Punt, N.
    Engelhardt, M.
    Schmitt-Hoffmann, A. H.
    Mouton, J. W.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2018, 7 (07): : 781 - 787
  • [4] Pharmacokinetics, Pharmacodynamics, and Safety of GB001 in Healthy Non-Asian, Non-Japanese Asian and Japanese Subjects
    Shen, J.
    Yamashita, M.
    Opiteck, G. J.
    Raghupathi, K.
    Woo, A.
    Aranda, R.
    Ortega, H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [5] Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib
    Dostalova, Hana
    Krystof, Vladimir
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (04)
  • [6] EFFECT OF CYP3A4 INHIBITORS ON THE PHARMACOKINETICS OF THE BRUTON'S TYROSINE KINASE INHIBITOR, EVOBRUTINIB, IN HEALTHY SUBJECTS.
    Dyroff, M.
    Port, A.
    Schmidt, R.
    Scheible, H.
    Luepfert, C.
    Bachmann, A.
    Mammasse, N.
    Mitchell, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S67 - S67
  • [7] SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND FOOD EFFECT OF AN ORAL BRUTON'S TYROSINE KINASE INHIBITOR HM71224 IN HEALTHY SUBJECTS
    Yoon, Y. -K.
    Hadi, S.
    Iersel, T. V.
    Sin, H. J.
    Lee, K. O.
    Lee, J.
    Song, J. Y.
    Jang, S.
    Lee, Y. -M.
    Kang, J.
    Suh, K. H.
    Son, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 231 - 231
  • [8] Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects
    Hall, Jesse
    Gillen, Michael
    Liu, Sha
    Miner, Jeffrey N.
    Valdez, Shakti
    Shen, Zancong
    Lee, Caroline
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 1799 - 1807
  • [9] Pharmacokinetics, pharmacodynamics, and safety of verinurad with and without allopurinol in healthy Asian, Chinese, and non-Asian participants
    Johansson, Susanne
    Han, David
    Hunt, Thomas
    Bjorck, Karin
    Florica, Delia
    Gillen, Michael
    Hall, Jesse
    Erlandsson, Fredrik
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2022, 10 (03):
  • [10] Effect of Itraconazole or Rifampin on Itacitinib Pharmacokinetics When Administered Orally in Healthy Subjects
    Barbour, April M.
    Punwani, Naresh
    Epstein, Noam
    Landman, Robert
    Cimino, Evan
    Yuska, Brad
    Wang, Phillip
    He, Kevin
    Chen, Xuejun
    Yeleswaram, Swamy
    JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (12): : 1641 - 1647
12345